Tianjin TEDA Biomedical Engineering Co Ltd (8189) Fair Value & Analysis
Basic Materials · HK · Market cap HK$294M
Fair value as of: Jul 2, 2026
From 1 valuation models · updated 45 days ago
Share price +77.6% over the past month.
Below-average quality, and screening another 70% overvalued on our models.
What matters now
- Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 2, 2026.
How to read this chart
60‑month range HK$0.0610 – HK$0.6000 · the HK$0.2700 price screens above the HK$0.0800 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 2, 2026.
Analysis
Tianjin TEDA Biomedical Engineering Co Ltd (8189) currently trades at HK$0.2700, while our model-based Fair Value estimate is HK$0.0800, implying the stock looks roughly 70.4% overvalued today. The Quality Score stands at 34/100 (below-average quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Tianjin TEDA Biomedical Engineering Co Ltd generated revenue of HK$523M at a net margin of -17.4%. Revenue grew 7.0% year over year. Net debt stands at HK$80.6M. Fundamentals as of Jul 2, 2026
The share trades about 50% below its 52-week high and 137% above its 52-week low, currently below its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -17% fair-value upside, at -70%, 8189 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when 8189 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 2, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 32 · Market factors (momentum, volatility) 34
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Tianjin TEDA Biomedical Engineering Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of biological compound fertilizer products in the People's Republic of China. It operates through Fertiliser Products, and AI health & elderly care products and services segments.
Full company description
Tianjin TEDA Biomedical Engineering Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of biological compound fertilizer products in the People's Republic of China. It operates through Fertiliser Products, and AI health & elderly care products and services segments. The company's biological compound fertilizer products include active fertilizer, mixture with nitrogen, phosphorus, and potassium with various formulas. It also involved in the provision of integrated elderly and health care; elderly equipment leasing services; elderly-related products sales; warehousing services; processing and licensing of the fertiliser products; sales of gold products for elderly customers, such as gold amulets and bracelets; sales of chips and servers supporting healthcare solutions; research and development of elderly care business; and elderly care consulting, advisory, management, and assessment services. In addition, the company provides and licenses electroencephalography photography (EEG) diagnosis detection services and conducts EEG detection and diagnosis technology services. Further, the company engages in the research, development, manufacture, and application of biomedical science and technology projects; regional soil resources conditioning and remediation research services; provision of soil environmental quality standards research services; development and application of AI medical large model and MaaS platform; AI life and health project expansion; and data cleaning, database, and data intelligence analysis full-process data services. Tianjin TEDA Biomedical Engineering Company Limited was incorporated in 2000 and is headquartered in Tianjin, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Tianjin TEDA Biomedical Engineering Co Ltd reported revenue of HK$509M in FY2025 versus HK$476M in FY2021, a compound +1.7%/yr. Reported net income was −HK$88.5M in FY2025.
8189 screens 70% overvalued. Compare with Corteva, Inc →
Peer Group
Agricultural Inputs · 178 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Agricultural Inputs median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Agricultural Inputs stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Corteva, Inc CTVA | $76.22 | $27.81 | -64% |
| Nutrien Ltd NTR | C$93.60 | C$81.69 | -13% |
| Qinghai Salt Lake Industry Co 000792 | ¥27.65 | ¥21.26 | -23% |
| CF Industries Holdings CF | $120.01 | $161.00 | +34% |
| SABIC Agri-Nutrients Company 2020 | 122.90 SAR | 127.31 SAR | +4% |
| Yara International ASA YAR | kr 418.10 | kr 67.25 | -84% |
| Yunnan Yuntianhua Co 600096 | ¥29.82 | ¥42.12 | +41% |
| Asia-potash International Investment (Guangzhou)Co.,Ltd., 000893 | ¥45.86 | ¥38.01 | -17% |
| Coromandel International Limited COROMANDEL | ₹2,089 | ₹1,129 | -46% |
| UPL Limited UPL | ₹570.50 | ₹387.06 | -32% |
Compare Tianjin TEDA Biomedical Engineering Co Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is Tianjin TEDA Biomedical Engineering Co Ltd (8189) overvalued or undervalued?
What is the fair value of 8189?
What is the quality score of 8189?
What is the revenue of Tianjin TEDA Biomedical Engineering Co Ltd (8189)?
What is the net profit margin of 8189?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Tianjin TEDA Biomedical Engineering Co Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.